H.C. Wainwright Upgrades Context Therapeutics (CNTX) to Buy, 'CTIM-76 could be more effective than competitors'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to H.C. Wainwright Upgrades Context Therapeutics (CNTX) to Buy, 'CTIM-76 could be more effective than competitors'

Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76

October 31, 2023 9:00 AM EDT

CTIM-76 exhibits dose-proportional tumor responses and safety in preclinical models

Benchmarking studies comparing CTIM-76 with clinical-stage CLDN6 therapies support CTIM-76's differentiated product profile

CTIM-76 IND filing on track for late Q1 2024

Data to be presented at SITC 38th Annual Meeting on November 3rd

PHILADELPHIA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Context or the Company) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced encouraging preclinical data regarding the Companys preclinical asset,... More